16 July 2024
DLA Piper advises Alimera Sciences in acquisition by ANI Pharmaceuticals
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Andrew Gilbert Lead | DLA Piper | Partner | Corporate | Not stated |
| Jeffrey Scharfstein Lead | DLA Piper | Partner | Not stated | Not stated |
| Scott Cowan Lead | DLA Piper | Partner | Not stated | Not stated |
| Brian Hamano | DLA Piper | Partner | Not stated | Not stated |
| Rita Patel | DLA Piper | Partner | Not stated | Not stated |
| Georgia Jolink | DLA Piper | Partner | Not stated | Not stated |
| Jeff Aronson | DLA Piper | Partner | Not stated | Not stated |
| Heather Borthwick | DLA Piper | Partner | Not stated | Not stated |
| Paolo Morante | DLA Piper | Partner | Not stated | Not stated |
| Victoria McGuire | DLA Piper | Associate | Not stated | Not stated |
| Vincent Schiavoni | DLA Piper | Associate | Not stated | Not stated |
| Jessica Stenglein | DLA Piper | Associate | Not stated | Not stated |
Stated terms
- Stated value
- USD 381m (US$381 million)
- What the figure measures
- Total transaction value
- Client
- Alimera Sciences, Inc.Sell-side
- Counterparties
- ANI Pharmaceuticals (Buy-side)